Lupin, YL Biologics receive PMDA approval for Etanercept biosimilar in Japan

26 Mar 2019 Evaluate

YL Biologics (YLB), a joint venture between Lupin's subsidiary Lupin Atlantis Holdings SA (LAHSA) and Yoshindo Inc. in Japan, and Lupin (through its Japanese subsidiary, Kyowa Pharmaceutical Industry) have received an approval from Pharmaceutical and Medical Devices Agency (PMDA) to manufacture and sell their biosimilar Etanercept in Japan. The approval to treat moderate to severe Rheumatoid Arthritis (RA) and Juvenile Idiopathic Arthritis was received on March 26, 2019.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2113.40 -25.25 (-1.18%)
02-Feb-2026 09:45 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1613.85
Dr. Reddys Lab 1190.50
Cipla 1309.40
Zydus Lifesciences 875.45
Lupin 2113.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×